Energy metabolism: a useful target, an incomplete explanation

Fatigue makes energy metabolism an understandable place to look. The report considers mitochondrial function and muscle energetics as possible contributors to reduced capacity. It also offers an important restraint on that explanation: changing an energy-related measurement may not change the entire illness.

“Low energy” is an experience with several possible contributors

Someone may use the phrase to describe sleepiness, muscle fatigability, difficulty concentrating, lack of endurance or delayed worsening after activity. These experiences can overlap, but they are not interchangeable measurements of mitochondrial function.

An investigation becomes more useful when it starts with the specific limitation. Is a task difficult during performance? Does recovery take longer than expected? Does the next day bring a broad symptom flare? Those patterns lead to different questions, including the PEM branch when delayed worsening is present. 3

Creatine illustrates partial improvement

A randomized trial in fibromyalgia found improvements in muscle phosphocreatine and strength without broad improvements across pain, sleep and other clinical outcomes. The study is particularly useful because it measured the proposed target and symptoms separately. 1

For the report’s systems model, this supports a possibility rather than a complete treatment conclusion: capacity in one subsystem can improve while other maintaining factors remain. It also supplies a test of overly simple explanations. If better muscle energetics does not reliably reduce pain, pain cannot be assumed to be a direct readout of that one variable.

CoQ10: an early clinical signal

A small, short trial associated with Mario Cordero’s work reported clinical and molecular changes with CoQ10. Its size and duration limit what can be concluded about dependable benefit, long-term outcomes and which people are likely to respond. 2

That is enough to justify a focused research question. It is not enough to treat every product containing CoQ10 as equivalent to the tested intervention or to assume that combining it with several other ingredients will improve the result.

Why an ingredient study is not a blend study

A formulation changes more than the ingredient list. Amounts, chemical forms, extraction methods, absorption, other ingredients and the population using it can all differ from the research setting. A biological rationale for each component does not establish the effectiveness of the combination.

This matters especially on a publication connected to a supplement business. The studies discussed here are evidence about their own interventions. They are not trials of Functional Fascia products and should not be presented as such.

Choose the outcome before the experiment

If an individually reviewed intervention is considered, the question should name its intended benefit: completing a particular task, recovering more predictably, or changing a clinically meaningful symptom. A vague goal of “supporting mitochondria” is difficult to evaluate.

Decide what improvement would justify the ongoing cost and effort, and what adverse response would lead to stopping or reassessment. Starting several products together makes attribution harder and complicates an interaction review. The report’s strongest practical idea here is disciplined learning: a mechanism suggests a question; the person’s response and the broader evidence determine what happens next.

Educational publication, not individualized medical advice. Functional Fascia also sells supplements; the studies here did not test our products. Editorial and commercial context · Suggest a correction